ArticleMedicine2018

Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study.

Shuai Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.